Maintenance therapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs, zanzalintinib and durvalumab, as maintenance therapy for people with advanced liver cancer who have already responded to an initial treatment. The goal is to see if this combination can keep the cancer from growing longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer that cannot be removed with surgery or has spread.
- You have already been treated with a combination of durvalumab and tremelimumab and your cancer has responded or stayed stable.
- You are 18 years or older.
- You are able to perform daily activities with some help (ECOG performance status 0-2).
- Your liver and kidney function are within acceptable levels, and your blood counts are adequate.
- You have not had certain heart, bleeding, or gastrointestinal conditions recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (zanzalintinib, durvalumab, and tremelimumab) for people with liver cancer that cannot be removed by surgery and who have not received prior systemic treatment. The goal is to see if this combination can shrink or slow the growth of the cancer.
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
This Phase 2 trial tests three medicines together (durvalumab, tremelimumab, and bevacizumab) to treat non-surgical (non-resectable) liver cancer. It may help shrink tumors and slow disease progression by boosting the immune system and blocking tumor blood supply.
This study tests a new oral medication called zanzalitinib, which may help slow the growth of advanced prostate cancer that has continued to spread despite hormone therapy and possibly chemotherapy. The goal is to see if the drug is safe and effective for men with this type of cancer.
This trial combines three treatments: Y-90 radioembolization (targeted radiation to liver tumors), two immunotherapy drugs (durvalumab and tremelimumab), and a targeted oral drug (zanzalintinib) to see if this combination can shrink or control liver cancer that cannot be removed by surgery or transplant. It may be an option for people whose cancer has not spread beyond the liver and who have not had prior systemic treatment.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.